About Contact Us Careers
Sign In

Non-Small Cell Lung Cancer Treatment Market - Top Companies and Manufacturers

  • Report ID: 3024
  • Published Date: Sep 23, 2024
  • Report Format: PDF, PPT

Companies Dominating the Non-Small Cell Lung Cancer Treatment Landscape

    • Genentech, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis 
    • Celgene Corporation (Bristol Myers Squibb)
    • AstraZeneca plc
    • Elli Lilly & Company
    • Pfizer, Inc.
    • Sanofi
    • Astellas Pharma, Inc.
    • Novartis AG
    • Takeda Oncology
Browse Key Market Insights with Data Illustration:

In the News


Author Credits:  Radhika Pawar


  • Report ID: 3024
  • Published Date: Sep 23, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising prevalence of non-small cell lung cancer, and the growing awareness about the disease are the key factors driving market growth.

The market is anticipated to attain a high CAGR over the forecast period, i.e., 2021-2029.

The limited treatment options for non-small cell lung cancer and lack of awareness about the disease in lower economic regions are estimated to hamper market growth.

The market in Asia Pacific region will provide ample growth opportunities owing to the increasing diagnosis rates of non-small cell lung cancer.

The major players dominating the non-small cell lung cancer treatment market are Genentech, Inc., Celgene Corporation, AstraZeneca plc, and Elli Lilly & Company among others.
Inquiry Before Buying Request Free Sample

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample